… Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with
impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J …

… kinases to become pharmacologically active. Subsequently, it … Monitoring of liver function
during treatment is recommended … and oxaliplatin could be used in the context of patients with …

… to a minimum respecting the dilutions that guarantee pharmacological stability; (II) the dialysis
… Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. …

… Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with
impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J …

… patients with HD who measured oxaliplatin (L-… a dose-escalating pharmacologic *Corresponding
authors: Hiroshi Osawa, Department of Oncology and Hematology, Edogawa Hospital, …

… of oxaliplatin is not necessarily needed if hemodialysis is performed soon after the infusion.
Further studies are needed to distinguish between active and inactive oxaliplatin products …

… patients administered with oxaliplatin. Thus, at a constant dose of oxaliplatin, patients with
impaired renal function … systemic fPt levels do not increase oxaliplatin-induced hematological, …

… dosing, there was improved liver function, lower incidence of … failure to recognize impaired
kidney function is critically important ( 20 ). In a study of patients with metastatic colon cancer …

… At baseline, the patient had normal hepatic function and no signs of ascites or pleural effusion.
The laboratory findings on admission were as follows: white blood cell count 4250/mm 3 , …

… usually a reflection of end-organ dysfunction (hepatic, renal), … Dose-escalating and
pharmacological study of oxaliplatin in … Cancer Institute Organ Dysfunction Working Group Study. J …